Acta Neuropathologica

, Volume 120, Issue 5, pp 585–592

Molecular diagnostics of gliomas: the clinical perspective

  • Ghazaleh Tabatabai
  • Roger Stupp
  • Martin J. van den Bent
  • Monika E. Hegi
  • Jörg C. Tonn
  • Wolfgang Wick
  • Michael Weller
Review

DOI: 10.1007/s00401-010-0750-6

Cite this article as:
Tabatabai, G., Stupp, R., van den Bent, M.J. et al. Acta Neuropathol (2010) 120: 585. doi:10.1007/s00401-010-0750-6

Abstract

Significant progress has been made in the molecular diagnostic subtyping of brain tumors, in particular gliomas. In contrast to the classical molecular markers in this field, p53 and epidermal growth factor receptor (EGFR) status, the clinical significance of which has remained controversial, at least three important molecular markers with clinical implications have now been identified: 1p/19q codeletion, O6-methylguanine methyltransferase (MGMT) promoter methylation and isocitrate dehydrogenase-1 (IDH1) mutations. All three are favorable prognostic markers. 1p/19q codeletion and IDH1 mutations are also useful to support and extend the histological classification of gliomas since they are strongly linked to oligodendroglial morphology and grade II/III gliomas, as opposed to glioblastoma, respectively. MGMT promoter methylation is the only potentially predictive marker, at least for alkylating agent chemotherapy in glioblastoma. Beyond these classical markers, the increasing repertoire of anti-angiogenic agents that are currently explored within registration trials for gliomas urgently calls for efforts to identify molecular markers that predict the benefit derived from these novel treatments, too.

Keywords

Clinical neurooncologyMolecular diagnosticPrognostic factorMalignant gliomasClinical trials

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Ghazaleh Tabatabai
    • 1
  • Roger Stupp
    • 2
  • Martin J. van den Bent
    • 3
  • Monika E. Hegi
    • 2
  • Jörg C. Tonn
    • 4
  • Wolfgang Wick
    • 5
  • Michael Weller
    • 1
  1. 1.Department of NeurologyUniversity Hospital ZurichZurichSwitzerland
  2. 2.Department of NeurosurgeryCentre Hospitalier Universitaire Vaudois and University of LausanneLausanneSwitzerland
  3. 3.Neuro-Oncology Unit, Daniel de Hoed Cancer Centre/ErasmusUniversity Hospital RotterdamRotterdamThe Netherlands
  4. 4.Department of NeurosurgeryUniversity of Munich LMUMunichGermany
  5. 5.Department of Neurooncology, Neurology Clinic and National Center for Tumor DiseaseUniversity of HeidelbergHeidelbergGermany